The authors regret that, in Fig. 4, a hazard ratio was missing for the FHSI-8 symptom item Discomfort or Pain in Stomach. Please see the corrected figure here.
Corrigendum to ‘Ramucirumab as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib: Patient-focused outcome results from the randomised phase III REACH study’ [Eur J Canc 81 (2017) 17–25]
Leggi l'articolo originale